-+ 0.00%
-+ 0.00%
-+ 0.00%

Lytix Biopharma Clarifies Subsequent Offering Is Capped at 1,875,000 New Shares

PUBT·11/18/2026 07:51:01
Lytix Biopharma Clarifies Subsequent Offering Is Capped at 1,875,000 New Shares
  • Lytix Biopharma corrected its November 18, 2026, announcement to specify a maximum of 1,875,000 new shares in its subsequent offering.
  • The offering would raise up to NOK 15 million at NOK 8 per share; all other information remains unchanged.
  • The company may cancel the offering if its shares trade at or below the subscription price in sufficient volumes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief via Cision (Ref. ID: 20261118:BIT:0839:0) on November 18, 2026, and is solely responsible for the information contained therein.